Genetics of rheumatoid arthritis susceptibility, severity, and treatment response

Seminars in Immunopathology

Volumn 39, Issue 4, 2017, Pages 395-408

  Viatte, Sebastien ^a   Barton, Anne ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; C REACTIVE PROTEIN; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER;

AMINO ACID SEQUENCE; ASIAN; CAUCASIAN; DAS28; DISEASE SEVERITY; EPIGENETICS; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HAPLOTYPE; HLA DRB1 GENE; HUMAN; IMMUNOGENETICS; IMMUNOPHENOTYPING; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; QUANTITATIVE TRAIT LOCUS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANIMAL; DISEASE MANAGEMENT; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; INHERITANCE; METABOLISM; PHARMACOGENETICS; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, RHEUMATOID; BIOMARKERS; DISEASE MANAGEMENT; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INHERITANCE PATTERNS; PHARMACOGENETICS; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85019692719     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-017-0630-4     Document Type: Review

References (139)

1. Rothschild BM, Turner KR, DeLuca MA (1988) Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. Science 241:1498–1501
2. Rogers J, Dieppe P (1990) Skeletal palaeopathology and the rheumatic diseases: where are we now? Ann Rheum Dis 49:885–886
3. Landre-Beauvais AJ (2001) The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Joint Bone Spine 68:130–143
4. Darwin CR, Wallace AR (1858) On the tendency of species to form varieties; and on the perpetuation of varieties and species by natural means of selection. J Proc Linn Soc, Zool 3:45–62
5. Mendel G (1866) Versuche über Pflanzenhybriden. Verh Nat forsch Ver Brünn 4:3–47
6. Dahm R (2005) Friedrich Miescher and the discovery of DNA. Dev Biol 278:274–288. doi:10.1016/j.ydbio.2004.11.028
7. Astorga GP, Williams RC Jr (1969) Altered reactivity in mixed lymphocyte culture of lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 12:547–554
8. Stastny P (1976) Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 57:1148–1157. doi:10.1172/JCI108382
9. Stastny P, Fink CW (1977) HLA-Dw4 in adult and juvenile rheumatoid arthritis. Transplant Proc 9:1863–1866
10. Stastny P (1978) Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 298:869–871. doi:10.1056/NEJM197804202981602
11. http://www.ebi.ac.uk/ipd/imgt/hla/. 2017. -
12. Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, Raychaudhuri S et al (2013) Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 8:e64683. doi:10.1371/journal.pone.0064683
13. http://hla.alleles.org/nomenclature/. 2017. -
14. Frisell T, Saevarsdottir S, Askling J (2016) Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol 12:335–343. doi:10.1038/nrrheum.2016.52
15. Deighton CM, Walker DJ (1991) The familial nature of rheumatoid arthritis. Ann Rheum Dis 50:62–65
16. del JD, Luthra HS, Annegers JF, Worthington JW, Kurland LT (1984) The familial aggregation of rheumatoid arthritis and its relationship to the HLA-DR4 association. Am J Epidemiol 119:813–829
17. Grant SF, Thorleifsson G, Frigge ML, Thorsteinsson J, Gunnlaugsdottir B, Geirsson AJ, Gudmundsson M et al (2001) The inheritance of rheumatoid arthritis in Iceland. Arthritis Rheum 44:2247–2254
18. Hemminki K, Li X, Sundquist J, Sundquist K (2009) Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum 60:661–668. doi:10.1002/art.24328
19. Lawrence JS (1970) Heberden Oration, 1969. Rheumatoid arthritis—nature or nurture? Ann Rheum Dis 29:357–379
20. Wolfe F, Kleinheksel SM, Khan MA (1988) Prevalence of familial occurrence in patients with rheumatoid arthritis. Br J Rheumatol 27(Suppl 2):150–152
21. Aho K, Koskenvuo M, Tuominen J, Kaprio J (1986) Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 13:899–902
22. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30–37. doi:10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
23. Svendsen AJ, Holm NV, Kyvik K, Petersen PH, Junker P (2002) Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. BMJ 324:264–266
24. Svendsen AJ, Kyvik KO, Houen G, Junker P, Christensen K, Christiansen L, Nielsen C et al (2013) On the origin of rheumatoid arthritis: the impact of environment and genes—a population based twin study. PLoS One 8:e57304. doi:10.1371/journal.pone.0057304
25. Frisell T, Holmqvist M, Kallberg H, Klareskog L, Alfredsson L, Askling J (2013) Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum 65:2773–2782. doi:10.1002/art.38097
26. Yang J, Lee SH, Goddard ME, Visscher PM (2011) GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88:76–82. doi:10.1016/j.ajhg.2010.11.011
27. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, Madden PA et al (2010) Common SNPs explain a large proportion of the heritability for human height. Nat Genet 42:565–569. doi:10.1038/ng.608
28. Speed D, Hemani G, Johnson MR, Balding DJ (2012) Improved heritability estimation from genome-wide SNPs. Am J Hum Genet 91:1011–1021. doi:10.1016/j.ajhg.2012.10.010
29. Lee SH, Byrne EM, Hultman CM, Kahler A, Vinkhuyzen AA, Ripke S, Andreassen OA et al (2015) New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. Int J Epidemiol 44:1706–1721. doi:10.1093/ije/dyv136
30. Knevel R, Grondal G, Huizinga TW, Visser AW, Jonsson H, Vikingsson A, Geirsson AJ et al (2012) Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Ann Rheum Dis 71:707–709. doi:10.1136/annrheumdis-2011-200627
31. Plant D, Wilson AG, Barton A (2014) Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 10:329–337. doi:10.1038/nrrheum.2014.16
32. Umicevic MM, Janss L, Vermeulen SH, van de Laar MA, van Riel PL, Guchelaar HJ, Brunner HG et al (2015) Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. Ann Rheum Dis 74:2183–2187. doi:10.1136/annrheumdis-2014-205541
33. Sieberts SK, Zhu F, Garcia-Garcia J, Stahl E, Pratap A, Pandey G, Pappas D et al (2016) Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun 7:12460. doi:10.1038/ncomms12460
34. Kim K, Bang SY, Lee HS, Bae SC (2017) Update on the genetic architecture of rheumatoid arthritis. Nat Rev Rheumatol 13:13–24. doi:10.1038/nrrheum.2016.176
35. McAllister K, Eyre S, Orozco G (2011) Genetics of rheumatoid arthritis: GWAS and beyond. Open Access Rheumatol 3:31–46. doi:10.2147/OARRR.S14725
36. Terao C, Raychaudhuri S, Gregersen PK (2016) Recent advances in defining the genetic basis of rheumatoid arthritis. Annu Rev Genomics Hum Genet 17:273–301. doi:10.1146/annurev-genom-090314-045919
37. Viatte S, Plant D, Raychaudhuri S (2013) Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 9:141–153. doi:10.1038/nrrheum.2012.237
38. Yamamoto K, Okada Y, Suzuki A, Kochi Y (2015) Genetics of rheumatoid arthritis in Asia—present and future. Nat Rev Rheumatol 11:375–379. doi:10.1038/nrrheum.2015.7
39. Yarwood A, Huizinga TW, Worthington J (2016) The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford) 55:199–209. doi:10.1093/rheumatology/keu323
40. Yarwood A, Eyre S, Worthington J (2016) Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery. Expert Opin Drug Discov 11:805–813. doi:10.1080/17460441.2016.1195366
41. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506:376–381. doi:10.1038/nature12873
42. Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis arthritis rheum 30:1205–1213
43. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, Alfredsson L et al (2012) Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 44:291–296. doi:10.1038/ng.1076
44. de Vries N, Tijssen H, van Riel PL, van de Putte LB (2002) Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67–74 of the HLA-DRB1 molecule. Arthritis Rheum 46:921–928. doi:10.1002/art.10210
45. Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, Symmons DP et al (2015) Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA 313:1645–1656. doi:10.1001/jama.2015.3435
46. Han B, Diogo D, Eyre S, Kallberg H, Zhernakova A, Bowes J, Padyukov L et al (2014) Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet 94:522–532. doi:10.1016/j.ajhg.2014.02.013
47. Scally SW, Petersen J, Law SC, Dudek NL, Nel HJ, Loh KL, Wijeyewickrema LC et al (2013) A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 210:2569–2582. doi:10.1084/jem.20131241
48. Bossini-Castillo L, de KC, Kallberg H, van ‘t Slot R, Italiaander A, Coenen M, Tak PP et al (2015) A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. Ann Rheum Dis 74:e15. doi:10.1136/annrheumdis-2013-204591
49. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG et al (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75:330–337. doi:10.1086/422827
50. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Kawaguchi T et al (2012) Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 44:511–516. doi:10.1038/ng.2231
51. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y et al (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508–514. doi:10.1038/ng.582
52. McAllister K, Yarwood A, Bowes J, Orozco G, Viatte S, Diogo D, Hocking LJ et al (2013) Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. Arthritis Rheum 65:3058–3062. doi:10.1002/art.38183
53. Orozco G, Viatte S, Bowes J, Martin P, Wilson AG, Morgan AW, Steer S et al (2014) Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. Arthritis Rheumatol. 66:24–30. doi:10.1002/art.38196
54. Jiang L, Yin J, Ye L, Yang J, Hemani G, Liu AJ, Zou H et al (2014) Novel risk loci for rheumatoid arthritis in Han Chinese and congruence with risk variants in Europeans. Arthritis Rheumatol. 66:1121–1132. doi:10.1002/art.38353
55. Julia A, Gonzalez I, Fernandez-Nebro A, Blanco F, Rodriguez L, Gonzalez A, Canete JD et al (2016) A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis. Rheumatology (Oxford) 55:1106–1111. doi:10.1093/rheumatology/kew035
56. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, Alfredsson L et al (2011) A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70:259–265. doi:10.1136/ard.2009.126821
57. Terao C, Ohmura K, Kochi Y, Ikari K, Okada Y, Shimizu M, Nishina N et al (2015) Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. Arthritis Res. Ther. 17:104. doi:10.1186/s13075-015-0623-4
58. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A et al (2012) High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 44:1336–1340. doi:10.1038/ng.2462
59. Viatte S, Massey J, Bowes J, Duffus K, Eyre S, Barton A, Worthington J (2016) Replication of associations of genetic loci outside the HLA region with susceptibility to anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheumatol. 68:1603–1613. doi:10.1002/art.39619
60. Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J, Martin P et al (2013) Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet 45:664–669. doi:10.1038/ng.2614
61. Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, Blaschke P et al (2013) Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet 50:140–143. doi:10.1136/jmedgenet-2012-101411
62. Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A, Worthington J (2012) Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis 71:1984–1990. doi:10.1136/annrheumdis-2011-201225
63. Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH, Tohma S, Alfredsson L et al (2014) Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Ann Rheum Dis
64. Skinningsrud B, Lie BA, Husebye ES, Kvien TK, Forre O, Flato B, Stormyr A et al (2010) A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis. Ann Rheum Dis 69:1471–1474
65. Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, Alfredsson L, Toes R et al (2007) Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 56:2202–2210
66. Guo J, Wu X, Too CL, Yin F, Lu X, He J, Li R et al (2012) A replication study confirms the association of dendritic cell immunoreceptor (DCIR) polymorphisms with ACPA—negative RA in a large Asian cohort. PLoS One 7:e41228
67. Lorentzen JC, Flornes L, Eklow C, Backdahl L, Ribbhammar U, Guo JP, Smolnikova M et al (2007) Association of arthritis with a gene complex encoding C-type lectin-like receptors. Arthritis Rheum 56:2620–2632
68. Li C, Mu R, Guo J, Wu X, Tu X, Liu X, Hu F et al (2014) Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res. Ther. 16:R105. doi:10.1186/ar4554
69. Kochi Y, Suzuki A, Yamada R, Yamamoto K (2010) Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis. Nat Rev Rheumatol 6:290–295. doi:10.1038/nrrheum.2010.23
70. Okada Y, Kim K, Han B, Pillai NE, Ong RT, Saw WY, Luo M et al (2014) Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum Mol Genet 23:6916–6926. doi:10.1093/hmg/ddu387
71. Reynolds RJ, Ahmed AF, Danila MI, Hughes LB, Gregersen PK, Raychaudhuri S, Plenge RM et al (2014) HLA-DRB1-associated rheumatoid arthritis risk at multiple levels in African Americans: hierarchical classification systems, amino acid positions, and residues. Arthritis Rheumatol. 66:3274–3282. doi:10.1002/art.38855
72. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW et al (2016) Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 48:481–487. doi:10.1038/ng.3538
73. Hu X, Kim H, Stahl E, Plenge R, Daly M, Raychaudhuri S (2011) Integrating autoimmune risk loci with gene-expression data identifies specific pathogenic immune cell subsets. Am J Hum Genet 89:682. doi:10.1016/j.ajhg.2011.10.010
74. Trynka G, Sandor C, Han B, Xu H, Stranger BE, Liu XS, Raychaudhuri S (2013) Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 45:124–130. doi:10.1038/ng.2504
75. Martin P, McGovern A, Orozco G, Duffus K, Yarwood A, Schoenfelder S, Cooper NJ et al (2015) Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. Nat Commun 6:10069. doi:10.1038/ncomms10069
76. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, Ingle C et al (2009) Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325:1246–1250. doi:10.1126/science.1174148
77. Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shoresh N et al (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518:337–343. doi:10.1038/nature13835
78. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T et al (2014) Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344:519–523. doi:10.1126/science.1249547
79. Vahedi G, Kanno Y, Furumoto Y, Jiang K, Parker SC, Erdos MR, Davis SR et al (2015) Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 520:558–562. doi:10.1038/nature14154
80. Viatte S, Barton A (2012) The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease. European Musculoskeletal Review 7(2):102–107
81. Ling SF, Viatte S, Lunt M, Van Sijl AM, Silva-Fernandez L, Symmons DP, Young A et al (2016) HLA-DRB1 amino acid positions 11/13, 71, and 74 are associated with inflammation level, disease activity, and the health assessment questionnaire score in patients with inflammatory polyarthritis. Arthritis Rheumatol. 68:2618–2628. doi:10.1002/art.39780
82. Knevel R, Klein K, Somers K, Ospelt C, Houwing-Duistermaat JJ, van Nies JA, de Rooy DP et al (2014) Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann Rheum Dis 73:2038–2046. doi:10.1136/annrheumdis-2013-204050
83. de Rooy DP, Tsonaka R, Andersson ML, Forslind K, Zhernakova A, Frank-Bertoncelj M, de Kovel CG et al (2015) Genetic factors for the severity of ACPA-negative rheumatoid arthritis in 2 cohorts of early disease: a genome-wide study. J Rheumatol 42:1383–1391. doi:10.3899/jrheum.140741
84. Suzuki T, Ikari K, Yano K, Inoue E, Toyama Y, Taniguchi A, Yamanaka H et al (2013) PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study. PLoS One 8:e61045. doi:10.1371/journal.pone.0061045
85. van Steenbergen HW, Raychaudhuri S, Rodriguez-Rodriguez L, Rantapaa-Dahlqvist S, Berglin E, Toes RE, Huizinga TW et al (2015) Association of valine and leucine at HLA-DRB1 position 11 with radiographic progression in rheumatoid arthritis, independent of the shared epitope alleles but not independent of anti-citrullinated protein antibodies. Arthritis Rheumatol. 67:877–886. doi:10.1002/art.39018
86. Scott IC, Rijsdijk F, Walker J, Quist J, Spain SL, Tan R, Steer S et al (2015) Do genetic susceptibility variants associate with disease severity in early active rheumatoid arthritis? J Rheumatol 42:1131–1140. doi:10.3899/jrheum.141211
87. Ruyssen-Witrand A, van Steenbergen HW, van Heemst J, Gourraud PA, Nigon D, Lukas C, Miceli-Richard C et al (2015) A new classification of HLA-DRB1 alleles based on acid-base properties of the amino acids located at positions 13, 70 and 71: impact on ACPA status or structural progression, and meta-analysis on 1235 patients with rheumatoid from two cohorts (ESPOIR and EAC cohort). RMD. Open. 1:e000099. doi:10.1136/rmdopen-2015-000099
88. Kurreeman FA, Padyukov L, Marques RB, Schrodi SJ, Seddighzadeh M, Stoeken-Rijsbergen G, van der Helm-van Mil AH et al (2007) A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 4:e278
89. Mohamed RH, Pasha HF, El-Shahawy EE (2012) Influence of TRAF1/C5 and STAT4 genes polymorphisms on susceptibility and severity of rheumatoid arthritis in Egyptian population. Cell Immunol 273:67–72
90. Plant D, Thomson W, Lunt M, Flynn E, Martin P, Eyre S, Farragher T et al (2011) The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology (Oxford) 50:78–84
91. van Steenbergen HW, Rodriguez-Rodriguez L, Berglin E, Zhernakova A, Knevel R, Ivorra-Cortes J, Huizinga TW et al (2015) A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Res. Ther. 17:1. doi:10.1186/s13075-014-0514-0
92. Viatte S, Plant D, Lunt M, Fu B, Flynn E, Parker BJ, Galloway J et al (2013) Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage. J Rheumatol 40:144–156
93. Knevel R, de Rooy DP, Gregersen PK, Lindqvist E, Wilson AG, Grondal G, Zhernakova A et al (2012) Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts. Ann Rheum Dis 71:1753–1755
94. Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, Roberts R et al (2013) Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155:57–69. doi:10.1016/j.cell.2013.08.034
95. Viatte S, Lee JC, Fu B, Espeli M, Lunt M, De Wolf JN, Wheeler L et al (2016) Association between genetic variation in FOXO3 and reductions in inflammation and disease activity in inflammatory polyarthritis. Arthritis Rheumatol. 68:2629–2636. doi:10.1002/art.39760
96. van Steenbergen HW, Rantapaa-Dahlqvist S, van Nies JA, Berglin E, Huizinga TW, Gregersen PK, van der Helm-van Mil AH (2014) Does a genetic variant in FOXO3A predict a milder course of rheumatoid arthritis?—a multi-cohort study. Arthritis Rheum
97. Teare MD, Knevel R, Morgan MD, Kleszcz A, Emery P, Moore DJ, Conaghan P et al (2013) Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. Arthritis Rheum 65:2555–2561
98. Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G et al (2015) C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proc Natl Acad Sci U S A 112:11618–11623. doi:10.1073/pnas.1501947112
99. Knevel R, de Rooy DP, Zhernakova A, Grondal G, Krabben A, Steinsson K, Wijmenga C et al (2013) Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 65:1684–1693
100. Ruyssen-Witrand A, Lukas C, Nigon D, Dawidowicz K, Morel J, Sibilia J, Jamard B et al (2013) Association of IL-2RA and IL-2RB genes with erosive status in early rheumatoid arthritis patients (ESPOIR and RMP cohorts). Joint Bone Spine
101. van der Linden MP, Feitsma AL, le Cessie S, Kern M, Olsson LM, Raychaudhuri S, Begovich AB et al (2009) Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum 60:2242–2247
102. Maxwell JR, Marinou I, Kuet KP, Orozco G, Moore DJ, Barton A, Worthington J et al (2012) Rheumatoid arthritis-associated polymorphisms at 6q23 are associated with radiological damage in autoantibody-positive RA. J Rheumatol 39:1781–1785
103. Scherer HU, van der Linden MP, Kurreeman FA, Stoeken-Rijsbergen G, Cessie S, Huizinga TW, van der Helm-van Mil AH et al (2010) Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 69:567–570
104. Toonen EJ, Barrera P, Fransen J, de Brouwer AP, Eijsbouts AM, Miossec P, Marotte H et al (2012) Meta-analysis identified the TNFA-308G>A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis. Arthritis Res. Ther. 14:R264. doi:10.1186/ar4110
105. Krabben A, Wilson AG, de Rooy DP, Zhernakova A, Brouwer E, Lindqvist E, Saxne T et al (2013) Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts. Arthritis Rheum 65:3051–3057
106. Leipe J, Schramm MA, Prots I, Schulze-Koops H, Skapenko A (2014) Increased Th17 cell frequency and poor clinical outcome in rheumatoid arthritis are associated with a genetic variant in the IL-4R gene, rs1805010. Arthritis Rheum
107. Hussein YM, El-Shal AS, Rezk NA, Abdel Galil SM, Alzahrani SS (2013) Influence of interleukin-4 gene polymorphisms and interleukin-4 serum level on susceptibility and severity of rheumatoid arthritis in Egyptian population. Cytokine 61:849–855
108. de Rooy DP, Yeremenko NG, Wilson AG, Knevel R, Lindqvist E, Saxne T, Krabben A et al (2013) Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis 72:769–775. doi:10.1136/annrheumdis-2012-202184
109. de Rooy DP, Zhernakova A, Tsonaka R, Willemze A, Kurreeman BA, Trynka G, van Toorn L et al (2014) A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 73:1163–1169. doi:10.1136/annrheumdis-2013-203375
110. Knevel R, Krabben A, Wilson AG, Brouwer E, Leijsma MK, Lindqvist E, de Rooy DP et al (2013) A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 65:582–589
111. Han SW, Sa KH, Kim SI, Lee SI, Park YW, Lee SS, Yoo WH et al (2012) CCR5 gene polymorphism is a genetic risk factor for radiographic severity of rheumatoid arthritis. Tissue Antigens 80:416–423. doi:10.1111/j.1399-0039.2012.01955.x
112. Han SW, Sa KH, Kim SI, Lee SI, Park YW, Lee SS, Yoo WH et al (2012) FCRL3 gene polymorphisms contribute to the radiographic severity rather than susceptibility of rheumatoid arthritis. Hum Immunol 73:537–542. doi:10.1016/j.humimm.2012.02.011
113. Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, Lindqvist E, Saxne T et al (2012) Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis 71:1651–1657
114. Yoshida S, Ikari K, Yano K, Toyama Y, Taniguchi A, Yamanaka H, Momohara S (2014) Lack of association between IL-15 genetic variants and progression of joint destruction in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 73:784–785
115. Du Y, Cui Y, Liu X, Hu F, Yang Y, Wu X, Liu X et al (2014) Contribution of functional LILRA3, but not nonfunctional LILRA3, to sex bias in susceptibility and severity of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 66:822–830. doi:10.1002/art.38308
116. Juge PA, van Steenbergen HW, Constantin A, Tobon GJ, Schaeverbeke T, Gazal S, Combe B et al (2014) SPP1 rs9138 variant contributes to the severity of radiological damage in anti-citrullinated protein autoantibody-negative rheumatoid arthritis. Ann Rheum Dis 73:1840–1843. doi:10.1136/annrheumdis-2014-205539
117. Knevel R, de Rooy DP, Saxne T, Lindqvist E, Leijsma MK, Daha NA, Koeleman BP et al (2014) A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Res. Ther. 16:R108. doi:10.1186/ar4558
118. Rodriguez-Rodriguez L, Ivorra-Cortes J, Carmona FD, Martin J, Balsa A, van Steenbergen HW, van der Helm-van Mil AH et al (2015) PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts. Arthritis Res Ther 17:306. doi:10.1186/s13075-015-0830-z
119. Danila MI, Westfall AO, Raman K, Chen L, Reynolds RJ, Hughes LB, Arnett DK et al (2015) The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis. Genes Immun 16:446–451. doi:10.1038/gene.2015.24
120. Marinou I, Maxwell JR, Wilson AG (2010) Genetic influences modulating the radiological severity of rheumatoid arthritis. Ann Rheum Dis 69:476–482. doi:10.1136/ard.2009.117721
121. Hyrich KL, Watson KD, Silman AJ, Symmons DP (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45:1558–1565. doi:10.1093/rheumatology/kel149
122. Kourbeti IS, Ziakas PD, Mylonakis E (2014) Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 58:1649–1657. doi:10.1093/cid/ciu185
123. Shea M, Costa DB, Rangachari D (2016) Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 10:113–129. doi:10.1177/1753465815617871
124. Cobb J, Cule E, Moncrieffe H, Hinks A, Ursu S, Patrick F, Kassoumeri L et al (2014) Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharmacogenomics. J. 14:356–364. doi:10.1038/tpj.2014.3
125. Senapati S, Singh S, Das M, Kumar A, Gupta R, Kumar U, Jain S et al (2014) Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet Genomics 24:211–219. doi:10.1097/FPC.0000000000000036
126. Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I, Canete JD et al (2013) GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 14:727–734. doi:10.2217/pgs.13.60
127. Smith SL, Plant D, Lee XH, Massey J, Hyrich K, Morgan AW, Wilson AG et al (2016) Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics 17:715–720. doi:10.2217/pgs.16.16
128. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, Hughes LB et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62:1849–1861. doi:10.1002/art.27457
129. Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Canete JD, Raya E, Magro-Checa C, Vasilopoulos Y et al (2016) Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J 16:137–140. doi:10.1038/tpj.2015.29
130. Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A (2012) Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64:665–670. doi:10.1002/art.33381
131. Canhao H, Rodrigues AM, Santos MJ, Carmona-Fernandes D, Bettencourt BF, Cui J, Rocha FL et al (2015) TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. Biomed Res Int 2015:490295. doi:10.1155/2015/490295
132. Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F, Rapsomaniki P et al (2013) Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS One 8:e74375. doi:10.1371/journal.pone.0074375
133. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T et al (2013) Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 9:e1003394. doi:10.1371/journal.pgen.1003394
134. Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, Wilson AG et al (2015) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford) 54:494–499. doi:10.1093/rheumatology/keu358
135. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM (2016) Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open 2:e000171. doi:10.1136/rmdopen-2015-000171
136. van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D (2013) Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 72:1680–1686. doi:10.1136/annrheumdis-2012-202407
137. Baker JF, Conaghan PG, Smolen JS, Aletaha D, Shults J, Emery P, Baker DG et al (2014) Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol 66:794–802. doi:10.1002/art.38304
138. MacIsaac KD, Baumgartner R, Kang J, Loboda A, Peterfy C, DiCarlo J, Riek J et al (2014) Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients. PLoS One 9:e113937. doi:10.1371/journal.pone.0113937
139. Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas DA, Kremer J et al (2015) A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis 74:170–176. doi:10.1136/annrheumdis-2013-204133